title: Neuromuscular pharmacology in rat neonates: development of responsiveness to prototypic blocking and reversal drugs.
abstract: The neonatal pharmacology of neuromuscular drugs was studied in vivo in newborn rats and in vitro in neonatal phrenic nerve-hemidiaphragm preparations. Drugs used to probe neuromuscular development in rat neonates were physostigmine, edrophonium, neostigmine, 4-aminopyridine, d-tubocurarine (dTc), and succinylcholine. The prejunctional actions of these drugs were monitored in relation to neonatal age by the appearance of stimulus-evoked repetitive discharge initiated by motor nerve endings and the occurrence and magnitude of the resulting enhancement of twitch tension. The occurrence and incidence of drug-induced fasciculations also served to track the development of functional motor nerve endings. Each of these prejunctional actions was inoperative until the third neonatal week, indicative of incomplete motor nerve development. In contrast, 4-aminopyridine, a nonanticholinesterase, evoked these prejunctional actions in 1-wk-old rat neonates. Neostigmine and edrophonium antagonized dTc as early as the first week; presumably, postsynaptic maturation had reached a functional level. 4-Aminopyridine also antagonized dTc at week 1. Rat neonates showed resistance to dTc blockade when tested by neonatal phrenic nerve-hemidiaphragm preparations in vitro. Relationships between age and 85%-95% transmission block declined to the adult level by week 5. This result indicates that in rat neonates, pharmacodynamic rather than pharmacokinetic mechanisms predominate in the development of responsiveness to dTc.
authors.affiliation: Department of Pharmacology, Cornell University Medical College, New York, NY 10021.
authors.forename: M
authors.initials: M
authors.lastname: Okamoto
authors.forename: J L
authors.initials: JL
authors.lastname: Walewski
authors.forename: J F
authors.initials: JF
authors.lastname: Artusio
authors.forename: W F
authors.initials: WF
authors.lastname: Riker
mesh_terms: D015761:4-Aminopyridine / Q000494:pharmacology; D000375:Aging / Q000502:physiology; D000818:Animals; D000831:Animals, Newborn / Q000502:physiology*; D002800:Cholinesterase Inhibitors / Q000494:pharmacology*; D003472:Curare / Q000037:antagonists & inhibitors; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D004491:Edrophonium / Q000494:pharmacology; D005207:Fasciculation / Q000139:chemically induced; D005260:Female; D008297:Male; D009119:Muscle Contraction / Q000187:drug effects; D009388:Neostigmine / Q000494:pharmacology; D009411:Nerve Endings / Q000187:drug effects / Q000254:growth & development; D009466:Neuromuscular Blocking Agents / Q000494:pharmacology*; D009469:Neuromuscular Junction / Q000187:drug effects / Q000254:growth & development* / Q000502:physiology; D010830:Physostigmine / Q000494:pharmacology; D051381:Rats; D011919:Rats, Inbred Strains; D013390:Succinylcholine / Q000494:pharmacology; D009435:Synaptic Transmission / Q000187:drug effects; D014403:Tubocurarine / Q000494:pharmacology
chemical_list: D002800:Cholinesterase Inhibitors; D009466:Neuromuscular Blocking Agents; D009388:Neostigmine; D004491:Edrophonium; D003472:Curare; D010830:Physostigmine; D015761:4-Aminopyridine; D013390:Succinylcholine; D014403:Tubocurarine